Rhinomed Limited (RNO.AX)

Rhinomed Limited (RNO.AX) — VMCI valuation read

RNO.AX screens at VMCI 33/100, a 17-point gap below the Healthcare sector median (50). For a mid-cap Rhinomed Limited share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

RNO.AX has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: RNO.AX trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -2.1x leaves covenant headroom, which sets the rate-cycle exposure for Rhinomed Limited.

RNO.AX fell 2.0% over the trailing 7 days, with a -19.6% read on a 30-day basis.